Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISV-101
- Development stage
- Unknown
- Lead developer
- Sun Pharma
- Modality
- Small Molecules, Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
ISV-101 is a novel ophthalmic drug candidate developed by InSite Vision for the treatment of dry eye disease. It combines a low dose of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s proprietary DuraSite delivery technology, which enhances ocular drug retention and absorption. The mechanism of action involves inhibition of cyclooxygenase 1 and 2 (COX-1 and COX-2) pathways, thereby reducing inflammation associated with dry eye disease. ISV-101 was designed to address unmet needs in dry eye therapy by providing effective anti-inflammatory action with improved ocular bioavailability due to the DuraSite vehicle[1][3][4][5][9].
- Brand names
- Acunac
- Other names
- bromfenac sodium
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on ISV-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISV-101.